NCT05967481 Evaluation of Study Experiences of Neuroendocrine Tumor Patients Status NOT_YET_RECRUITING Phase N/A
NCT05922579 A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET Status TERMINATED Phase N/A
NCT05918302 Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. Status RECRUITING Phase PHASE3
NCT05894486 Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors Status NOT_YET_RECRUITING Phase PHASE2
NCT05871320 Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms Status COMPLETED Phase EARLY_PHASE1
NCT05870423 Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors Status RECRUITING Phase PHASE1
NCT05804331 The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study Status RECRUITING Phase N/A
NCT05746208 Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors Status RECRUITING Phase PHASE2
NCT05709171 Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms Status ENROLLING_BY_INVITATION Phase PHASE2
NCT05565066 A Real-world Comparison of FNB and FNA in IHC-required Lesions. Status COMPLETED Phase N/A
NCT05554003 Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study Status RECRUITING Phase PHASE2
NCT05513469 Biomarker Identification of Radionuclide Therapy-induced Radiation Responses Status UNKNOWN Phase NA
NCT05500391 Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Status RECRUITING Phase PHASE2
NCT05477576 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Status RECRUITING Phase PHASE3
NCT05475210 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors Status RECRUITING Phase PHASE1
NCT05459844 A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs Status ACTIVE_NOT_RECRUITING Phase PHASE3